Deep Learning–Based Estimated Pulmonary Biological Age From Chest Computed Tomography Images in Healthy Adults: Model Development and Validation Study Background: Estimated pulmonary biological age (ePBA) has emerged as a more reliable indicator for disease progression and mortality than chronological age, with chest computed tomography (CT) as a promising tool for calculating ePBA. However, the lack of models trained and validated with large-scale healthy adults hinders the generalizability of the CT-based ePBA. Objective: This study aims to develop an aging biomarker (ePBA) from multicenter chest CTs of healthy adults using deep learning and investigate the association between age gap (ePBA - chronological age) and pulmonary function as well as all-cause mortality in patients with chronic obstructive pulmonary disease (COPD). Methods: We used 11,187 chest CT scans from healthy adults at 3 health management centers and used multiple deep learning models. Of these, 7726 scans from institution A were used for model development. The remaining CT scans from institutions B (n=1506) and C (n=1955) served as external test datasets. To examine whether ePBA provided information beyond chronological age in patients with the disease, we investigated the association of age gap with lung function and all-cause mortality among 138 patients with COPD hospitalized at the same time period in institution A. Results: The deep learning models demonstrated acceptable applicability for this task and exhibited a strong correlation between ePBA and chronological age. Age gap was significantly associated with forced expiratory volume in 1 second expressed as percentage of predicted values reduction (=−0.18; =.03) and an increased risk of all-cause mortality (hazard ratio: 1.16, 95% CI 1.08-1.25) in patients with COPD. Conclusions: This study developed and validated a biomarker of aging—ePBA—with deep learning models based on chest CT. Age gap could serve as a novel clinical biomarker in patients with COPD.

New in JMIR Aging: Deep Learning–Based Estimated Pulmonary Biological Age From Chest Computed Tomography Images in Healthy Adults: Model Development and Validation Study #DeepLearning #PulmonaryHealth #BiologicalAge #CTImaging #COPD

Graphic titled "New in the CF News" highlights a study showing severe CF flareups cause temporary pulmonary hypertension in 1 in 4 kids. Age and inflammation linked to PH risk in children with CF. Source: Cystic Fibrosis News Today.

CF Research Update: https://bit.ly/4ru3mLM

A new study reports that one in four children hospitalized with severe cystic fibrosis flareups experienced temporary pulmonary hypertension.

#CysticFibrosis #CysticFibrosisNewsToday #Bionews #CFResearch #PulmonaryHealth

Bronchitis Treatment Market Size, Growth Outlook 2035 Bronchitis Treatment Market is expected to grow from 8.302 (USD Billion) in 2024 to 12.49 (USD Billion) by 2035. The Bronchitis Treatment Market CAGR (growth rate) is expected to be around 3.78% durin...

Increasing respiratory diseases are driving growth in the Bronchitis Treatment Market globally. Learn more! www.marketresearchfuture.com/reports/bron...
#RespiratoryCare #PulmonaryHealth #Pharma

Daily Microplastic Inhalation Rates Estimated in Study Using Raman spectroscopy and based on extrapolated concentrations measured in residential and car cabin environments, researchers found that adults may inhale up to 68,000 microplastic particles daily...

New estimates suggest adults may inhale up to 68,000 microplastic particles daily from indoor air. Most are in the 1 to 10 µm range—small enough to reach deep lung tissue. Higher levels were found in car cabins than in homes.

#PulmonaryHealth #EnvironmentalExposure #MedSky

Respiratory Therapeutic Devices Market Size, Share 2032 | MRFR Respirtory Therapeutic Devices Market to grow at a CAGR over 4.55% during the forecast period, | Respirtory Therapeutic Devices Industry Analysis by Product, Technology, Application, and End Users

Breath by breath, these devices support life across the Americas.
#RespiratoryCare #BreathEasy #TherapyDevices #PulmonaryHealth

www.marketresearchfuture.com/reports/resp...

🌬️ Breathe Easy with Tele-ICU
Asthma is manageable—with the right support.
Our team provides:
✅ Remote monitoring
✅ Early intervention
✅ Personalized care

🩺 Every breath counts.

#AsthmaAwareness #TeleICU #PulmonaryHealth #VirtualCare

Trevi Therapeutics Reports Positive Phase 2b Results in Chronic Cough Associated with Idiopathic Pulmonary Fibrosis Study met primary endpoint across all doses; Phase 3 program expected to begin in first half of 2026 following FDA meeting Trevi Therapeutics, Inc. (Nasdaq:

#TVRI reports encouraging Phase 2b results for chronic cough in IPF patients. Their investigational therapy shows promise in reducing cough frequency and improving quality of life.
#TreviTherapeutics
#PulmonaryHealth #ClinicalTrials #TreviTherapeutics
prismmarketview.com/trevi-therap...

Childhood Wheeze May Be Tied to Ozone Levels Early-life ozone exposure was linked to increased odds of asthma and wheeze in children aged 4 to 6 years.

New data suggest a potential link between ozone exposure and persistent childhood wheeze. Implications for pulmonary health may warrant closer review. #PulmonaryHealth #MedSky

4/6 More Findings:

🔹 Shorter hospital stays: 1 day for RFA vs. 8 days for resection (P < 0.001)
🔹 Highlights RFA as a viable alternative for patients declining surgery

#MinimallyInvasive #Radiology #PulmonaryHealth #MedResearch

The Impact of SARS-CoV-2 Viral Load on Long-Term Lung Health 🌬️🧬
📚 Key Insights from a Six-Month Study on Post-COVID Respiratory Health:
buff.ly/40zdxTy
#LongCOVID #PulmonaryHealth #RespiratoryCare #COVID19Research #ViralLoad

Unplug today. Reset.

#Unplug
#Unplugged
#Rest
#Relax
#ChronicIllness
#Bronchiectasis
#BronchiectasisInfo
#BeClearMethodToLivingWithBronchiectasis
#NTM
#MAC
#Reset #ResetYourMind #ResetYourself #PulmonaryHealth #PulmonaryWellness #ChronicDisease #Sleep #SleepWell #BetterSleep #annelamont

Study reveals ferroptosis as a major driver of severe COVID-19 lung damage Ferroptosis, an iron-dependent cell death mechanism, is identified as a key factor in severe COVID-19 lung disease, suggesting potential new therapeutic targets.

Study reveals ferroptosis as a major driver of severe COVID-19 lung damage 🔬🦠🫁 www.news-medical.net/news/2024052... #COVID19 #SARSCoV2 #Ferroptosis #LungDisease #ARDS #PulmonaryHealth #IronDependent #CellDeath #MedicalResearch @natureportfolio.bsky.social